Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2016

View Archived Issues

Data presented on brentuximab vedotin in germ-cell tumors

Daiichi Sankyo divulges new S1PL inhibitors

Aryl-sulfonamides as isoform-selective inhibitors of Nav1.7

A first-in-human study of RG-7666

Allied-Bristol Life Sciences launches new subsidiary iBeCa Therapeutics

Microlin Bio to acquire Marina's nucleic acid therapeutic assets

Mologen announces extension of TEACH study

Vraylar now available in the U.S. as treatment of adults with bipolar mania and schizophrenia

FDA grants breakthrough therapy designation for NI-0501 for the treatment of primary HLH

MP-376 receives QIDP designation

Sanofi and DiCE Molecules announce research collaboration

BioBlast Pharma announces positive final results from HOPEMD phase II study

Istituto Europeo di Oncologia patents KDM1A inhibitors

Synergistic anticancer effects of GEN-1 combined with Avastin and Doxil in preclinical studies

Merck & Co. discloses DGAT-2 inhibitors

AstraZeneca exercises option to acquire rights to Orexo's OX-CLI program

Nippon Shinyaku develops JAK1 inhibitors

TES Pharma presents ACMSD inhibitors

Amgen divulges Mcl-1 inhibitors

Grant supports City of Hope's development of treatment for Canavan disease

Cleveland BioLabs updates progress of entolimod pre-EUA review

MDxHealth launches SelectMDx for Prostate Cancer test in U.S.

Proof of concept achieved in phase IIa trial of VTP-43742 for psoriasis

VESTRI safety study of Advair Diskus in children meets primary endpoint

FDA approves Kovaltry for hemophilia A in children and adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...